La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Merus Gestione

Gestione criteri di controllo 4/4

Merus' Il CEO è Bill Lundberg, nominato in Dec2019, e ha un mandato di 4.67 anni. la retribuzione annua totale è $ 4.67M, composta da 13.9% di stipendio e 86.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.22% delle azioni della società, per un valore di $ 7.86M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.7 anni e 6 anni.

Informazioni chiave

Bill Lundberg

Amministratore delegato

US$4.7m

Compenso totale

Percentuale dello stipendio del CEO	13.9%
Mandato del CEO	4.8yrs
Proprietà del CEO	0.2%
Durata media del management	3.8yrs
Durata media del Consiglio di amministrazione	6.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Sep 20

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Aug 14

Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Jun 01

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

May 24

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 12

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

Dec 18

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Sep 19

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Jun 20

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

May 24

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 08

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Aug 08

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Aug 02

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Jun 30

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

May 14

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Apr 25

New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

Mar 03

We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

Nov 25

News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Aug 08

Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

Jul 28

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Jul 02

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Bill Lundberg rispetto agli utili di Merus?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$168m
Mar 31 2024	n/a	n/a	-US$150m
Dec 31 2023	US$5m	US$650k	-US$155m
Sep 30 2023	n/a	n/a	-US$177m
Jun 30 2023	n/a	n/a	-US$178m
Mar 31 2023	n/a	n/a	-US$152m
Dec 31 2022	US$6m	US$599k	-US$131m
Sep 30 2022	n/a	n/a	-US$64m
Jun 30 2022	n/a	n/a	-US$54m
Mar 31 2022	n/a	n/a	-US$76m
Dec 31 2021	US$8m	US$582k	-US$67m
Sep 30 2021	n/a	n/a	-US$80m
Jun 30 2021	n/a	n/a	-US$89m
Mar 31 2021	n/a	n/a	-US$79m
Dec 31 2020	US$5m	US$565k	-US$86m
Sep 30 2020	n/a	n/a	-US$83m
Jun 30 2020	n/a	n/a	-US$69m
Mar 31 2020	n/a	n/a	-US$65m
Dec 31 2019	US$162k	n/a	-US$55m

Compensazione vs Mercato: La retribuzione totale di Bill ($USD 4.67M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 6.73M ).

Compensazione vs guadagni: La retribuzione di Bill è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Bill Lundberg (61 yo)

4.8yrs

Mandato

US$4,671,327

Compensazione

Dr. Sven Ante Lundberg, also known as Bill, M.D. is Venture Advisor of Forge Life Science Partners. He serves as Chief Executive Officer, President and Executive Director of Merus N.V. since December 31, 2...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Sven Lundberg	CEO, President & Executive Director	4.8yrs	US$4.67m	0.22% $ 7.3m
Gregory Perry	Chief Financial Officer	1.3yrs	US$6.21m	0% $ 0
Peter Silverman	EVP, Company Secretary	6.6yrs	US$1.95m	0% $ 0
Andrew Joe	Consultant	4.2yrs	US$1.66m	0% $ 0
Hennie Hoogenboom	Co-Founder and Scientific Advisor	no data	Nessun dato	Nessun dato
Harry Shuman	Chief Accounting Officer	no data	Nessun dato	0.010% $ 334.4k
Cornelis de Kruif	CTO & Executive VP	11.7yrs	US$609.22k	Nessun dato
Cecilia Anna Geuijen	Chief Scientific Officer & Senior VP	3.3yrs	Nessun dato	Nessun dato
Kathleen Farren	IR & Corporate Communications Officer	no data	Nessun dato	Nessun dato
Alexander Berthold Bakker	Executive VP	no data	US$647.63k	Nessun dato
Shannon Campbell	Executive VP & Chief Commercial Officer	2.6yrs	Nessun dato	Nessun dato
Ashley Pereira	Senior Vice President of Regulatory Affairs	2.7yrs	Nessun dato	Nessun dato

3.8yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di MRUS è considerato esperto (durata media dell'incarico 3.7 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Sven Lundberg	CEO, President & Executive Director	5.3yrs	US$4.67m	0.22% $ 7.3m
Elaine Jones	Board Observer	14.7yrs	Nessun dato	Nessun dato
Maxine Gowen	Independent Non-Executive Director	3.3yrs	US$305.06k	0% $ 0
Anand Mehra	Independent Chairman	9.1yrs	US$417.56k	0% $ 0
Paolo Pucci	Independent Non-Executive Director	4.3yrs	US$309.56k	0% $ 0
Mark Iwicki	Independent Non Executive Director	9.3yrs	US$311.06k	0.11% $ 3.5m
Antoni Ribas	Member of Scientific Advisory Board	6.1yrs	Nessun dato	Nessun dato
Victor Sandor	Independent Non-Executive Director	5.3yrs	US$303.56k	0% $ 0
Josep Tabernero Caturla	Member of Scientific Advisory Board	6.1yrs	Nessun dato	Nessun dato
Antonius Schumacher	Member of Scientific Advisory Board	6.1yrs	Nessun dato	Nessun dato
Jason Haddock	Independent Non-Executive Director	less than a year	Nessun dato	Nessun dato
Len Kanavy	Independent Non-Executive Director	6.2yrs	US$303.56k	0% $ 0

6.1yrs

Durata media

59.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MRUS sono considerati esperti (durata media dell'incarico 6 anni).

Merus Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Merus N.V. Announces Chief Medical Officer Changes

Merus N.V. Appoints Jason Haddock as Non-Executive Director

Merus N.V., Annual General Meeting, May 07, 2024

EVP, Company Secretary notifies of intention to sell stock

Merus Appoints Greg Perry as Chief Financial Officer

Independent Non Executive Director exercised options to buy US$1.5m worth of stock.

Recent updates

We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

Merus N.V. Announces Chief Medical Officer Changes

Merus N.V. Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab At the 2024 ASCO® Annual Meeting

Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Merus N.V. has completed a Follow-on Equity Offering in the amount of $400.15 million.

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Price target increased by 21% to US$73.36

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

Consensus revenue estimates increase by 26%

Merus N.V. Announces Petosemtamab Grants Breakthrough Therapy Designation by the U.S. FDA

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans

First quarter 2024 earnings released: US$0.59 loss per share (vs US$0.86 loss in 1Q 2023)

Merus N.V. Appoints Jason Haddock as Non-Executive Director

Merus N.V., Annual General Meeting, May 07, 2024

Price target increased by 7.6% to US$59.18

Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Price target increased by 16% to US$51.60

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up

Merus Stock: Rally Seems Overdone

Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

EVP, Company Secretary notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.60 loss

Consensus estimates of losses per share improve by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Merus N.V. Announces Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

New major risk - Revenue and earnings growth

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

U.S. Food and Drug Administration Grants Second Breakthrough Therapy Designation for zenocutuzumab (Zeno) of Merus N.V

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Merus Appoints Greg Perry as Chief Financial Officer

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$3.63 loss

Independent Non Executive Director exercised options to buy US$1.5m worth of stock.

Price target increased by 8.6% to US$40.67

Price target increased by 8.5% to US$39.67

Chief Business Officer exercised options to buy US$1.9m worth of stock.

Full year 2022 earnings released: US$2.92 loss per share (vs US$1.73 loss in FY 2021)

Now 21% undervalued

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Merus N.V. Announces Executive Changes

Price target decreased to US$37.11

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$38.44

Merus N.V. Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Merus N.V. Presents Clinical Data on Zenocutuzumab in NRG1-Fusion Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates increase by 15%

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Merus N.V., Annual General Meeting, May 31, 2022

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Executive VP exercised options and sold US$947k worth of stock

Merus N.V. Announces Publication of Abstract on MCLA-129 At the American Association for Cancer Research 2022 Annual Meeting

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)